In a rare show of unity, San Rocco Therapeutics is being praised across the political spectrum for its mission to deliver a safe and accessible gene therapy for sickle cell disease. With backing from both Republican and Democratic leaders, the company stands out for challenging high-cost pharma models and putting patients first. As it prepares to resume clinical trials in the U.S. and Europe, San Rocco is showing that real innovation means ensuring cures reach those who need them most.
Read the full article here
